141 related articles for article (PubMed ID: 35703355)
1. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
[TBL] [Abstract][Full Text] [Related]
2. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
3. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
9. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
[TBL] [Abstract][Full Text] [Related]
10. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S; López B; Ferreira JP; Girerd N; Bozec E; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Moreno MU; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Cleland JGF; Zannad F; Díez J; González A;
Eur J Heart Fail; 2022 Feb; 24(2):321-331. PubMed ID: 34841615
[TBL] [Abstract][Full Text] [Related]
12. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
[TBL] [Abstract][Full Text] [Related]
13. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides.
Ravassa S; Lupón J; López B; Codina P; Domingo M; Revuelta-López E; Moreno MU; San José G; Santiago-Vacas E; Cediel G; Roncal C; Díez J; Bayés-Genís A; González A
JACC Heart Fail; 2023 Jan; 11(1):58-72. PubMed ID: 36599551
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of biomarkers of collagen synthesis and ventricular function and dyssynchrony in adolescents and young adults after repair of tetralogy of Fallot.
Lai CT; Chan KW; Wong SJ; Chow PC; Cheung YF
Am Heart J; 2011 Sep; 162(3):467-73. PubMed ID: 21884862
[TBL] [Abstract][Full Text] [Related]
16. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.
Jellis CL; Sacre JW; Wright J; Jenkins C; Haluska B; Jeffriess L; Martin J; Marwick TH
Eur Heart J Cardiovasc Imaging; 2014 Jul; 15(7):776-86. PubMed ID: 24472731
[TBL] [Abstract][Full Text] [Related]
17. Effect of High Thoracic Sympathetic Nerve Block on Serum Collagen Biomarkers in Patients with Chronic Heart Failure.
Sun G; Liu F; Qu R
Cardiology; 2017; 136(2):102-107. PubMed ID: 27591776
[TBL] [Abstract][Full Text] [Related]
18. Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension.
Rojek A; Cielecka-Prynda M; Przewlocka-Kosmala M; Laczmanski L; Mysiak A; Kosmala W
J Hum Hypertens; 2014 Sep; 28(9):557-63. PubMed ID: 24718382
[TBL] [Abstract][Full Text] [Related]
19. The Role of Circulating Collagen Turnover Biomarkers and Late Gadolinium Enhancement in Patients with Non-Ischemic Dilated Cardiomyopathy.
Revnic R; Cojan-Minzat BO; Zlibut A; Orzan RI; Agoston R; Muresan ID; Horvat D; Cionca C; Chis B; Agoston-Coldea L
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741245
[TBL] [Abstract][Full Text] [Related]
20. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation.
Swartz MF; Fink GW; Sarwar MF; Hicks GL; Yu Y; Hu R; Lutz CJ; Taffet SM; Jalife J
J Am Coll Cardiol; 2012 Oct; 60(18):1799-806. PubMed ID: 23040566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
